EVIO Inc. Launches EVIO Biosciences Division; Dr. Anthony Smith to Lead Biosciences Division
May 24, 2018 at 08:00 am EDT
Share
EVIO Inc. announced the launch of its EVIO Biosciences Division. EVIO Biosciences will explore combination drug therapeutics through in vitro and clinical research. The new division reflects the growing need for education and broader dissemination of cannabis and cannabinoid biotechnology research in the scientific and medical community, particularly in the face of the widespread changes to cannabis regulation worldwide.
The division will be led by EVIO's Chief Science Officer, Dr. Anthony Smith. This allows EVIO to leverage its scientific and human capital expertise to focus on development of intellectual property and research. The division's goals encompass emerging health benefits and advanced delivery modes for cannabinoids and cannabis products to the human endocannabinoid system.
EVIO, Inc. is a diversified holding company. The Company provides analytical testing services to the agricultural and pharmaceutical industries, primarily for cannabis, hemp, and related products. The Company offers residential and commercial construction services. The Company also offers research and development and consulting services for participants in the cannabis and hemp industries. The Company tests products to verify the regulatory requirements for sale. Its subsidiaries include Smith Scientific Industries, LLC; Greenhaus Analytical Labs, LLC; Viridis Analytics, LLC; EVIO Labs OR, Inc.; C3 Labs, LLC; EVIO Labs Humboldt, LLC and Keystone Labs, Inc.